



LKT Laboratories, Inc.

Ensartinib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID E543721

CAS No. 1365267-27-1

Chemical Name 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide

Synonym X396, X-396

Formula C₂₅H₂₅Cl₂FN₆O₃

Formula Wt. 547.41

Melting Point

Purity ≥98%

Solubility DMSO:100 mg/mL (178.11 mM)


Ethanol:100 mg/mL (178.11 mM)

Water: Insoluble

Store Temp -20°C

Ship Temp Ambient

Description Ensartinib is a third-generation ALK inhibitor. In addition, ensartinib is found to also have activity against ROS1, MET, SLK, Axl, LTK, ABL and EPHA2.



Bulk quantities available upon request

| Product ID | Size |
|------------|--------|
| E543721 | 5 mg |
| E543721 | 25 mg |
| E543721 | 100 mg |

References Horn L, Wakelee H, Reckamp KL, et al. MINI01.02: Response and plasma genotyping from phase I/II trial of ensartinib (X-396) in patients (pts) with ALK+ NSCLC: topic: medical oncology. J Thorac Oncol. 2016 Nov;11(11S):S256-S257. PMID: 27969449

Caccese M, Ferrara R, Pilotto S, et al. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. PMID: 27682212

Dholaria B, Hammond W, Shreders A, et al. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016 Dec 9;9(1):138. PMID: 27938382

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.